دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Population Health and Human Rights
Julio Frenk, M.D., M.P.H., Ph.D., and Octavio Gómez-Dantés, M.D., M.P.H.
doi : 10.1056/NEJMp2101770
N Engl J Med 2021; 385:865-868
Covid-Induced Changes in Health Care Delivery — Can They Last?
Rachel M. Werner, M.D., Ph.D., and Sherry A. Glied, Ph.D.
doi : 10.1056/NEJMp2110679
N Engl J Med 2021; 385:868-870
Paying for Digital Health Care — Problems with the Fee-for-Service System
Julia Adler-Milstein, Ph.D., and Ateev Mehrotra, M.D.
doi : 10.1056/NEJMp2107879
N Engl J Med 2021; 385:871-873
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Alejandro Jara, Ph.D., Eduardo A. Undurraga, Ph.D., Cecilia González, M.D., Fabio Paredes, M.Sc., Tomás Fontecilla, M.Sc., Gonzalo Jara, B.S.E., Alejandra Pizarro, M.D., Johanna Acevedo, M.S., Katherinne Leo, B.S.E., Francisco Leon, M.B.A., Carlos Sans, B.S.E., Paulina Leighton, B.S.E., Pamela Suárez, B.S.E., Heriberto García-Escorza, M.S., and Rafael Araos, M.D.
doi : 10.1056/NEJMoa2107715
N Engl J Med 2021; 385:875-884
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.
Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia
Charlotte A. Bradbury, M.D., Ph.D., Julie Pell, Pg.C., Quentin Hill, M.D., Catherine Bagot, M.D., Nichola Cooper, M.D., Jenny Ingram, Ph.D., Katie Breheny, Ph.D., Rebecca Kandiyali, Ph.D., Rachel Rayment, M.D., Ph.D., Gillian Evans, M.D., Kate Talks, M.D., Ian Thomas, M.Sc., and Rosemary Greenwood, M.Sc.
doi : 10.1056/NEJMoa2100596
N Engl J Med 2021; 385:885-895
Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side effects, variable responses, and high relapse rates are serious drawbacks.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein, M.D., Naveed Sattar, M.D., Ph.D., Julio Rosenstock, M.D., Chinthanie Ramasundarahettige, M.Sc., Richard Pratley, M.D., Renato D. Lopes, M.D., Ph.D., Carolyn S.P. Lam, M.B., B.S., Ph.D., Nardev S. Khurmi, M.D., Laura Heenan, M.Sc., Stefano Del Prato, M.D., Leanne Dyal, M.Sc., and Kelley Branch, M.D. for the AMPLITUDE-O Trial Investigators*
doi : 10.1056/NEJMoa2108269
N Engl J Med 2021; 385:896-907
Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Martin Eklund, Ph.D., Fredrik Jäderling, M.D., Ph.D., Andrea Discacciati, Ph.D., Martin Bergman, M.D., Magnus Annerstedt, M.D., Markus Aly, M.D., Ph.D., Axel Glaessgen, M.D., Ph.D., Stefan Carlsson, M.D., Ph.D., Henrik Grönberg, M.D., Ph.D., and Tobias Nordström, M.D., Ph.D. for the STHLM3 consortium*
doi : 10.1056/NEJMoa2100852
N Engl J Med 2021; 385:908-920
High rates of overdiagnosis are a critical barrier to organized prostate cancer screening. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address this challenge, but the implications of its use in the context of organized prostate cancer screening are unknown.
Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells
Andrea Lisco, M.D., Ph.D., Amy P. Hsu, B.S., Dimana Dimitrova, M.D., Diana M. Proctor, Ph.D., Emily M. Mace, Ph.D., Peiying Ye, Ph.D., Megan V. Anderson, R.N., B.A., Stephanie N. Hicks, R.N., B.S.N., Christopher Grivas, B.S., Dima A. Hammoud, M.D., Maura Manion, M.D., Gabriel J. Starrett, Ph.D., Alvin Farrel, Ph.D., Kerry Dobbs, M.S., Isaac Brownell, M.D., Ph.D., Christopher Buck, Ph.D., Luigi D. Notarangelo, M.D., Jordan S. Orange, M.D., Ph.D., Warren J. Leonard, M.D., Michael I. Orestes, M.D., Anju T. Peters, M.D., Jennifer A. Kanakry, M.D., Julia A. Segre, Ph.D., Heidi H. Kong, M.D., and Irini Sereti, M.D., M.H.S.
doi : 10.1056/NEJMoa2102715
N Engl J Med 2021; 385:921-929
Chronic Meningitis
Allen J. Aksamit, M.D.
doi : 10.1056/NEJMra2032996
N Engl J Med 2021; 385:930-936
Abdominopelvic Actinomycosis
Noriko Arakaki, M.D., and Yusuke Oshiro, M.D.
doi : 10.1056/NEJMicm2102632
N Engl J Med 2021; 385:937
Loiasis
Sven Kalbitz, M.D., and Thomas Grünewald, M.D.
doi : 10.1056/NEJMicm2101227
N Engl J Med 2021; 385:e28
Inadequate Support
Cayla Pichan, B.S., Gurpreet Dhaliwal, M.D., Alice Cusick, M.D., Sanjay Saint, M.D., M.P.H., and Nathan Houchens, M.D.
doi : 10.1056/NEJMcps2108909
N Engl J Med 2021; 385:938-944
Effectiveness of an Inactivated SARS-CoV-2 Vaccine
Annelies Wilder-Smith, M.D., Ph.D., and Kim Mulholland, M.B., B.S., M.D.
doi : 10.1056/NEJMe2111165
N Engl J Med 2021; 385:946-948
Immune Thrombocytopenia Treatment
Paula H.B. Bolton-Maggs, D.M., and James N. George, M.D.
doi : 10.1056/NEJMe2110953
N Engl J Med 2021; 385:948-950
Audio Interview: A New Round of Rising Covid-19 Numbers
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2114471
N Engl J Med 2021; 385:e41
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
doi : 10.1056/NEJMc2108829
N Engl J Med 2021; 385:951-953
Household Transmission of SARS-CoV-2 from Children and Adolescents
doi : 10.1056/NEJMc2031915
N Engl J Med 2021; 385:954-956
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
doi : 10.1056/NEJMc2110897
N Engl J Med 2021; 385:956-957
Trial of Endovascular Treatment of Basilar-Artery Occlusion
doi : 10.1056/NEJMc2109962
N Engl J Med 2021; 385:958-960
